Table II.
Tumor-responsive promoters used to enhance oHSV efficacy.
| Trigger (Ref.) | Virus | Cancer | Promoter gene | Comments |
|---|---|---|---|---|
| DF3/MUC1 (164) | 3616 | Colon, melanoma, pancreas | RL1 | Tumor-responsive promoters applied through helper virus |
| Hypoxia (76) | G207 + 10xHRE | Colon to liver | RR1 | |
| CEA (68) | G207 | CR | RR1 | |
| AFP (69) | G207+ | Liver (HCC) | RR1 | |
| Androgen (prostate-specific) (74) | CgalΔ3 | Prostate | ICP4 | |
| Nestin (70) | rQNestin34.5 | Brain | RL1 | Nestin has been shown to play a critical role in HSV infection across a wide range of cell types |
| Musashi1 (71, 72) | dvM345: G207 + M345 KeM34.5: (G207) |
Glioma, NSCLC Glioma |
RL1 | – |
| T-cell factor (78) | bM24-TE (hrR3) | Colon, HCC | ICP4 | Response depended on the specific mutation in APC (between 1st and 2nd 20-amino-acid repeats) |
| URR16 (165) | HSPV-1 | Oral cancer | ICP4 | URR16 is an oral cancer-specific marker |
| B-Myb (166) | Myb34.5 | Colon | RL1 | – |
HCC, hepatocellular carcinoma; CR, colorectal cancer; NSCLC, non-small cell lung cancer.